Eurofins Scientific SE
Transplant Genomics announces launch of Trugraf Liver, the first and only non-invasive gene expression diagnostic test to optimise immunosuppression in liver transplant recipients - Seite 3
Shares in Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0014000MR3, Reuters EUFI.PA, Bloomberg ERF FP).
Until it has been lawfully made public widely by Eurofins through approved distribution channels, this document contains inside information for the purpose of Regulation (EU) 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse, as amended.
Important disclaimer:
This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgment of Eurofins Scientific’s management as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the information available to the Company’s management as of the date of publication, but no guarantees can be made as to their completeness or validity.
Lesen Sie auch
View source version on businesswire.com: https://www.businesswire.com/news/home/20220929005395/en/
The Eurofins Scientific Stock at the time of publication of the news with a fall of -0,15 % to 58,85EUR on Lang & Schwarz stock exchange (30. September 2022, 07:28 Uhr).